Alison A. Armour, M.B. Ch.B., B.Sc., M.Sc., M.D., FRCR, FRCP, Senior Vice President, Research and Development

Dr. Armour brings to Halozyme significant experience in all stages of oncology drug development, over 15 years of practice as a clinical oncologist, and a strong record of overseeing successful regulatory submissions. Dr. Armour joined Halozyme in May 2019 as Senior Vice President of Research and Development. She is responsible for Halozyme’s research, clinical development, regulatory, safety and pharmacovigilance efforts.

Prior to Halozyme, Dr. Armour served as the Chief Medical Officer at Endocyte, where she was responsible for the company’s clinical division, including all medical, clinical operations, regulatory, data management and pharmacovigilance activities. Prior to this role, she served as Vice President of Development and team lead for TYKERB® at GSK and then at Novartis. Earlier in her career, Dr. Armour also served as global medical science director at AstraZeneca.  She has co-authored two textbooks and more than 60 publications.

Dr. Armour received her B.Sc. in Biochemistry, her M.B., Ch.B. MSc, and Doctorate of Medicine from the University of Glasgow; her FRCR at the Royal College of Radiologists London, UK and her FRCP at the Royal College of Physicians in London, UK, for contributions to the field of oncology.


You are now leaving Halozyme is not responsible for or endorses the content of the linked site.